Monopar将在ANA年会上展示6年数据，显示ALXN 1840在UWDRDS第II和第III部分上持续改善威尔逊病的神经功能

Monopar Therapeutics Inc. (NASDAQ:MNPR) announced that new data on the long-term neurological efficacy and safety of its investigational therapy ALXN1840 (tiomolybdate choline) for Wilson disease will be presented at the 150th American Neurological Association (ANA) Annual Meeting on September 14-15, 2025.

Key findings to be presented at ANA include:

• Sustained Neurological Improvement: Statistically significant neurologic improvement from baseline on the Unified Wilson Disease Rating Scale ("UWDRS") Part II (patient-reported symptoms) and Part III (clinician-reported symptoms) was sustained over 6 years.
• Crossover Benefit: Patients who crossed over from standard of care ("SoC") to ALXN1840 showed additional neurological improvement, including a majority of patients who had worsened on SoC demonstrating a reversal on ALXN1840.
• Psychiatric Outcomes: Statistically significant psychiatric improvement from baseline was sustained over multiple years, as measured by the Brief Psychiatric Rating Scale ("BPRS").
• Consistency Across Trials: Neurological benefit was observed consistently across multiple independent studies.
• Favorable Safety Profile: Across more than 645 patient-years on ALXN1840, less than 1% of patients experienced a drug-related neurological serious adverse event ("SAE").